Ventiv Scientific's V-PULSE System Shows Promise in First Human Trials for Clot Removal
Ventiv Scientific announced successful first-in-human cases using its V-PULSE Mechanical Thrombectomy System, a novel device offering real-time aspiration control that could improve outcomes for patients with peripheral vascular clots while reducing blood loss.
Ventiv Scientific today announced the successful completion of its first-in-human clinical cases utilizing the V-PULSE Mechanical Thrombectomy System, a novel platform designed to remove blood clots from peripheral blood vessels. The cases mark a milestone in developing more effective treatments for thrombotic diseases such as deep vein thrombosis, acute limb ischemia, and pulmonary embolism.
Mechanical thrombectomy is increasingly critical for restoring blood flow, preserving limbs, and saving lives in patients with vascular blockages. The V-PULSE system distinguishes itself from conventional aspiration devices by providing physicians with real-time control over aspiration force at the catheter tip. This capability allows clinicians to rapidly adjust suction—starting, stopping, increasing, or decreasing as needed—potentially minimizing catheter clogging and reducing procedural blood loss.
“The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology,” said Dr. Makmood Razavi of St. Joseph Heart & Vascular Center in Orange, CA. “In our initial experience, the device demonstrated excellent control and procedural efficiency. Effective clot removal is critical for patients suffering from venous and arterial thrombotic disease, where delayed treatment can lead to serious complications.”
Traditional aspiration thrombectomy systems rely on continuous vacuum from syringes or electromechanical pumps, which can inadvertently remove substantial volumes of blood while attempting to extract clots. John O'Connor, President of Ventiv Scientific, explained that the V-PULSE platform was engineered to optimize aspiration efficiency and reduce blood loss while remaining compatible with existing hospital pumps. “Aspiration thrombectomy systems can remove substantial volumes of blood while attempting to extract thrombus,” O'Connor said. “The V-PULSE platform was engineered to provide physicians with procedural control, optimize aspiration efficiency, and potentially reduce blood loss while remaining compatible with aspiration pumps already available in hospitals today.”
Procedural success in thrombectomy depends on multiple factors, including clot age, composition, location, catheter design, and aspiration force. The V-PULSE system was developed to address these challenges through a differentiated control platform. The company's existing portfolio includes the FDA-cleared Control Aspire Mechanical Thrombectomy System for peripheral use and rapid-exchange catheters for peripheral and coronary applications. Additionally, Ventiv Scientific is developing next-generation technologies, including a multi-strut thrombectomy basket retrieval platform currently under investigation. These products have not yet received FDA clearance.
The successful first-in-human cases represent an important step forward for patients and physicians. By enhancing procedural control and efficiency, the V-PULSE system has the potential to improve outcomes for the millions affected by thrombotic vascular disease. More information is available at www.ventivscientific.com.